March 3, 2017
The Ministry of Health, Labor and Welfare said on March 2 that it has approved Celgene’s Revlimid (lenalidomide) for an additional indication of recurrent or refractory adult T-cell leukemia-lymphoma. Designated as an orphan drug, Revlimid will carry a reexamination period...read more